Article: ACTOS(R) Passes 3.5 Million Prescriptions.

More Than 1 Million Patients Using the Insulin Sensitizer to Treat

Type 2 Diabetes in the United States Alone

LINCOLNSHIRE, Ill., Dec. 6 /PRNewswire/ --

Takeda Pharmaceuticals America, Inc. today announced that their oral insulin sensitizer, ACTOS(R) (pioglitazone HCl), has passed the 3.5 million-prescription mark. Since ACTOS first became available in the United States in August of 1999, more than 1 million of the estimated 14 million Americans with type 2 diabetes have begun taking the drug and physicians have issued more than 3,512,000 prescriptions in the United States alone. ACTOS is co-promoted by Takeda and Eli Lilly & Co. within the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!